| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Not applicable. This compound is a chemical linker for bioconjugation, not a drug. It does not have a biological target. Its purpose is to attach a therapeutic payload (e.g., a toxin) to an antibody. The aminooxy group targets and forms a stable oxime bond with aldehyde- or ketone-modified payloads, while the amine can be further conjugated to a modified antibody. The PEG2 spacer enhances solubility and reduces steric hindrance.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
No significant direct in vitro activity reported. The compound is biologically inert. Its value is in enabling the synthesis of ADCs. The resulting ADC conjugates can demonstrate potent in vitro activity, killing targeted cancer cells with high specificity. The cleavable nature allows for efficient payload release in the target cell. The purity of the linker is typically ≥95% for successful conjugation. |
| ln Vivo |
No specific in vivo data reported. As a linker, it is not studied directly in vivo. However, ADCs synthesized using this Fmoc-aminooxy-PEG2-NH2 linker can show strong in vivo efficacy in tumor xenograft models. The PEG spacer can help improve the pharmacokinetics (e.g., reduce aggregation, increase circulation time) of the ADC compared to non-PEGylated linkers.
|
| Enzyme Assay |
Not applicable. This is a chemical reagent used for bioconjugation. A typical conjugation protocol involves first deprotecting the Fmoc group of Fmoc-aminooxy-PEG2-NH2 using 20% piperidine in DMF. The resulting free aminooxy group can then react with a drug molecule containing a ketone or aldehyde group in a mildly acidic buffer (pH 4-5) to form a stable oxime linkage. The final drug-linker conjugate can then be purified and coupled to an antibody.
|
| Cell Assay |
Not applicable. The compound itself is not used in cell-based assays. However, the fully conjugated and purified ADC can be tested. Target-positive and target-negative cancer cells are seeded in 96-well plates at 5,000 cells/well. Cells are treated with serial dilutions of the ADC (1 pM to 100 nM) for 72-96 hours. Cell viability is measured by a luminescent CellTiter-Glo assay. The assay must be performed with both cell lines to calculate the specific cytotoxicity and selectivity index of the ADC.
|
| Animal Protocol |
No specific in vivo animal study protocols are documented for the linker itself. For an ADC synthesized with it, a typical protocol would involve establishing subcutaneous tumor xenografts of target-positive cancer cells (e.g., CD30-positive Karpas 299 cells) in 6-8 week old female SCID mice. Once tumors are established, the ADC would be administered intravenously at a single dose or weekly for 2-3 cycles at 1-10 mg/kg. Tumor growth inhibition and survival would be monitored. The linker's stability in circulation is a key endpoint, assessed by LC-MS analysis of plasma samples.
|
| ADME/Pharmacokinetics |
Not applicable for the linker. The PEG2 spacer is known to impart favorable properties on the final ADC. The PEGylation helps increase the ADC's solubility, reduce aggregation, and prevent non-specific uptake by phagocytes. This leads to a longer plasma half-life and a larger area under the curve (AUC) for the ADC compared to non-PEGylated conjugates.
|
| Toxicity/Toxicokinetics |
No toxicity data reported. Fmoc-aminooxy-PEG2-NH2 is a chemical reagent. Standard chemical safety precautions apply, including the use of PPE (gloves, goggles) and a fume hood. Avoid inhalation and skin contact. The linker itself is not toxic, but the final ADC payload (e.g., auristatin, maytansinoid) is highly potent and must be handled with extreme caution in a qualified biosafety level 2 (BSL-2) or chemical safety facility.
|
| References |
[1]. Siekmann J, et, al. Materials and methods for conjugating a water soluble fatty acid derivative to a protein. US20120190096A1.
|
| Additional Infomation |
This is a cleavable ADC linker. The Fmoc protecting group is base-labile. The aminooxy group is highly reactive for chemoselective conjugation. The PEG2 spacer has the exact formula of -O-CH2-CH2-O-CH2-CH2-, which increases hydrophilicity. The compound is also used in proteomics for capturing glycopeptides. It is a specialty chemical for advanced bioconjugation research. Not for therapeutic use. Molecular formula: C19H22N2O5; molecular weight: 358.39.
|
| Molecular Formula |
C19H22N2O5
|
|---|---|
| Molecular Weight |
358.39
|
| Exact Mass |
358.152
|
| CAS # |
190249-87-7
|
| PubChem CID |
88541230
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
26
|
| Complexity |
414
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(C3=CC=CC=C32)COC(=O)NOCCOCCON
|
| InChi Key |
PJENKAHPGFOITB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H22N2O5/c20-25-11-9-23-10-12-26-21-19(22)24-13-18-16-7-3-1-5-14(16)15-6-2-4-8-17(15)18/h1-8,18H,9-13,20H2,(H,21,22)
|
| Chemical Name |
9H-fluoren-9-ylmethyl N-[2-(2-aminooxyethoxy)ethoxy]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7903 mL | 13.9513 mL | 27.9026 mL | |
| 5 mM | 0.5581 mL | 2.7903 mL | 5.5805 mL | |
| 10 mM | 0.2790 mL | 1.3951 mL | 2.7903 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
